Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata City, Niigata, 951-8510, Japan.
Division of Bioinformatics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Surg Today. 2020 Nov;50(11):1443-1451. doi: 10.1007/s00595-020-02024-4. Epub 2020 May 22.
The 9th Japanese Classification of Colorectal Cancer (9th JSCCR) has two main differences from the TNM classification (8th AJCC): first, main or lateral lymph node metastasis is classified as jN3; second, tumor nodules (ND) are treated as lymph node metastasis. In this study, we verified the 9th JSCCR for rectal cancer, focusing on the differences with the 8th AJCC.
This retrospective analysis involved 212 patients with stage I-III rectal cancer. ND was evaluated using whole-mount sections. We evaluated the relapse-free survival of each staging system, and compared the prognostic significance of the different staging systems using the Akaike information criterion (AIC) and Harrell's concordance index (c-index).
Main or lateral lymph node metastasis was detected in nine of 212 (4%) patients. ND was detected in 79 of 212 (37%) patients. The best risk stratification power was observed in the 9th JSCCR (AIC, 759; c-index, 0.708) compared with the 7th JSCCR (AIC, 771; c-index, 0.681), 8th JSCCR (AIC, 768; c-index, 0.696), and the 8th AJCC (AIC, 766; c-index, 0.691).
The 9th JSCCR, which includes the concepts of jN3 and ND, is useful for the risk stratification of rectal cancer, and the contributes to precise decision-making for follow-up management and adjuvant therapy.
第 9 版日本结直肠癌分类(9th JSCCR)与 TNM 分类(8th AJCC)相比有两个主要区别:一是主或侧淋巴结转移归类为 jN3;二是肿瘤结节(ND)被视为淋巴结转移。本研究旨在验证 9th JSCCR 在直肠癌中的应用,重点关注其与 8th AJCC 的差异。
本回顾性分析纳入了 212 例 I-III 期直肠癌患者。采用全切片评估 ND。评估了每个分期系统的无复发生存率,并使用赤池信息量准则(AIC)和哈雷尔一致性指数(c-index)比较了不同分期系统的预后意义。
212 例患者中,9 例(4%)存在主或侧淋巴结转移,79 例(37%)存在 ND。与 7th JSCCR(AIC:771,c-index:0.681)、8th JSCCR(AIC:768,c-index:0.696)和 8th AJCC(AIC:766,c-index:0.691)相比,9th JSCCR 的风险分层能力最佳(AIC:759,c-index:0.708)。
包含 jN3 和 ND 概念的 9th JSCCR 有助于直肠癌的风险分层,并为随访管理和辅助治疗的决策提供更精确的依据。